U.S. Markets closed


NasdaqGS . Currency in USD
Add to watchlist
Interactive chart
Previous CloseN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
Avg. VolumeN/A
Market CapN/A
PE Ratio (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals4 months ago

    Mallinckrodt to pay $100 million in settlement with FTC

    Mallinckrodt has agreed to pay $100 million to settle Federal Trade Commission charges that it violated antitrust laws in relation to the market for Acthar, the company’s top-selling drug. The FTC alleges that Mallinckrodt and its Mallinckrodt ARD Inc. division, formerly known as Questcor Pharmaceuticals Inc., violated the laws when Questcor acquired “the rights to a drug that threatened its monopoly in the U.S. market” for adrenocortocotropic hormone drugs (ACTH) such as Acthar. Acthar is a specialty drug used to treat infantile spasms and other serious medical conditions.

  • Reuters4 months ago

    Mallinckrodt to pay $100 mln to settle U.S. probe on drug pricing

    Mallinckrodt Plc has agreed to pay $100 million to settle allegations that a subsidiary broke U.S. antitrust law by sharply increasing the price of a multiple sclerosis drug while ensuring that no rival medicine appeared on the market, the Federal Trade Commission said on Wednesday. Mallinckrodt's share price dropped sharply to just under $43 from above $49 on a report Wednesday, which proved incorrect, that the FTC would sue Mallinckrodt. In 2001, Questcor bought the rights to Acthar, a type of hormone-based drug used to treat infantile spasms as well as multiple sclerosis.

  • TheStreet.com4 months ago

    Mallinckrodt Hit With $100M Fine for Squelching Rival to Infant Seizure Drug

    Regulators say company squelched competing drug for infant seizures.